Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, Henk M., Plesner, Torben, Laubach, Jacob P., Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C., Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M., Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1506348

Cited by (1,000)

Items 201–300 of 1,000

CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity
Andrej Stoll, Heiko Bruns, Maximilian Fuchs, Simon Völkl, Falk Nimmerjahn, Meik Kunz, Matthias Peipp, Andréas Mackensen, Dimitrios Mougiakakos · 2021 · Leukemia
Current developments in immunotherapy in the treatment of multiple myeloma
M. Köhler, Christine Greil, Michael Hudecek, Sagar Lonial, Noopur S Raje, Ralph Wäsch, Monika Martha Engelhardt · 2018 · Cancer
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity
Brady, Pamlea N., Goel, Anupam, Johnson, Margaret A. · 2019 · Microbiology and Molecular Biology Reviews
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Laurens E. Franssen, Claudia A.M. Stege, Sonja Zweegman, Niels W.C.J. van de Donk, Inger S. Nijhof · 2020 · Journal of Clinical Medicine
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
María‐Victoria Mateos, Meletios Athanasios Dimopoulos, Michèle Cavo, Kenshi Suzuki, Stefan Tobias Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
Leo Rasche, Emmanuelle Ménoret, Valentina Dubljevic, Eline Menu, Karin Vanderkerken, Constantin Lapa, Torsten Steinbrunn, Manik Chatterjee, Stefan Tobias Knop, Johannes Düll et al. · 2016 · Clinical Cancer Research
Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences
Christopher R. McCudden, Joannes F.M. Jacobs, David F. Keren, Hélène Caillon, Thomas Dejoie, Kristian Andersen · 2017 · Clinical Biochemistry
Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia
Fátima Bayón-Calderón, Marı́a L. Toribio, Sara González-García · 2020 · International Journal of Molecular Sciences
Treatment of relapsed multiple myeloma: Evidence-based recommendations
Ceren Durer, Seren Durer, Sarah Lee, Rajshekhar Chakraborty, Mustafa Nadeem Malik, Abdul Rafae, Muhammad Abu Zar, Ahmad Kamal, Nathaniel Rosko, Christy Joy Samaras et al. · 2019 · Blood Reviews
Management of infusion-related reactions in cancer therapy: strategies and challenges
Ana Barroso, F. Estevinho, Venceslau Pinto Hespanhol, E. Teixeira, J. Ramalho-Carvalho, António Araújo · 2024 · ESMO Open
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
Shyril O’Steen, Melissa Comstock, Johnnie J. Orozco, Donald K. Hamlin, D. Scott Wilbur, Jon C. Jones, Aimee L. Kenoyer, Margaret E. Nartea, Yukang Lin, Brian W. Miller et al. · 2019 · Blood
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Kitsada Wudhikarn, Beatriz Wills, Alexander M. Lesokhin · 2020 · Best Practice & Research Clinical Haematology
Immunometabolism: signaling pathways, homeostasis, and therapeutic targets
Rongrong Xu, Xiaobo He, Jia Xu, Ganjun Yu, Yanfeng Wu · 2024 · MedComm
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
Inger S. Nijhof, Laurens E. Franssen, Mark‐David Levin, Gerard M.J. Bos, Annemiek Broijl, Saskia K. Klein, Harry R. Koene, Andries C. Bloem, Aart Beeker, Laura M. Faber et al. · 2016 · Blood
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Ingrid Teige, Linda Mårtensson, Björn Frendéus · 2019 · Frontiers in Immunology
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Davide Spica, Till Junker, Michael Dickenmann, Stefan Schaub, Jürg U. Steiger, Tanja Rüfli, Jörg P. Halter, Helmut Hopfer, Andreas Holbro, Patricia Hirt‐Minkowski · 2019 · Case Reports in Nephrology and Dialysis
CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update
Adam D. Cohen · 2018 · American Society of Clinical Oncology Educational Book
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Alba Matas‐Céspedes, Anna Vidal‐Crespo, Vanina Rodríguez, Neus Villamor, Julio Delgado, Eva Giné, Heleia Roca-Ho, Pablo R. Menéndez, Elı́as Campo, Armando López‐Guillermo et al. · 2016 · Clinical Cancer Research
CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice
Yinan Zhong, Fenghua Meng, Wen Zhang, Bin Li, Jan C. M. van Hest, Zhiyuan Zhong · 2020 · Journal of Controlled Release
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Danai Dima, Joshua Dower, Raymond L. Comenzo, Cindy Varga · 2020 · Cancer Management and Research
CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab
Lei Kang, Cuicui Li, Zachary T. Rosenkrans, Nan Huo, Zhao Chen, Emily B. Ehlerding, Yan Huo, Carolina A. Ferreira, Todd E. Barnhart, Jonathan W. Engle et al. · 2021 · Advanced Science
Systemic lupus erythematosus: history and modernity
Evgeny Lvovich Nasonov, S. K. Soloviev, Андрей Владимирович Аршинов · 2022 · Rheumatology Science and Practice
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Federica Costa, Benedetta Dalla Palma, Nicola Giuliani · 2019 · Cells
Treatment Options in Refractory Autoimmune Encephalitis
Alessandro Dinoto, Sérgio Ferrari, Sara Mariotto · 2022 · CNS Drugs
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Kamlesh Kumar Bisht, Taro Fukao, Marielle Chiron, Paul Gerard Guy Richardson, Djordje Atanackovic, Eduardo N. Chini, Wee Joo Chng, Helgi J. Van de Velde, Fabio Malavasi · 2023 · Cancer Medicine
Monoclonal antibodies — A new era in the treatment of multiple myeloma
Tomáš Jelı́nek, Roman Hájek · 2015 · Blood Reviews
Update of thrombosis in multiple myeloma
Frank W.G. Leebeek · 2016 · Thrombosis Research
Immunotherapies targeting CD38 in Multiple Myeloma
Djordje Atanackovic, Mary Nicole Steinbach, Sabarinath Venniyil Radhakrishnan, Tim Luetkens · 2016 · OncoImmunology
Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma
Andrea B. Moffitt, Sandeep S. Davé · 2017 · Journal of Clinical Oncology
Antibody-Based Cancer Therapy
Djoke Hendriks, Goda Choi, Marco de Bruyn, Valerie R. Wiersma, Edwin Bremer · 2017 · International review of cytology
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Arif E. Çetin, Mark M. Stevens, Nicholas L. Calistri, Mariateresa Fulciniti, Selim Olçum, Robert J. Kimmerling, Nikhil C. Munshi, Scott R. Manalis · 2017 · Nature Communications
ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab
Lei Kang, Dawei Jiang, Christopher G. England, Todd E. Barnhart, Bo Yu, Zachary T. Rosenkrans, Rongfu Wang, Jonathan W. Engle, Xiaojie Xu, Peng Huang et al. · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
Current use of monoclonal antibodies in the treatment of multiple myeloma
Cindy Varga, Michelle E. Maglio, Irene M. Ghobrial, Paul Gerard Guy Richardson · 2018 · British Journal of Haematology
Multiple myeloma in the very elderly patient: challenges and solutions
Andrew J King, Toby Andrew Eyre, Faye Amelia Sharpley, Caroline S. Watson, Karthik Ramasamy, John Willan · 2016 · Clinical Interventions in Aging
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
Kerstin Schütze, Katharina Petry, Julia Hambach, Niklas Schuster, William Fumey, Levin Schriewer, Jana Larissa Röckendorf, Stephan Menzel, Birte Albrecht, Friedrich Haag et al. · 2018 · Frontiers in Immunology
Targeted Alpha-Particle Therapy for Hematologic Malignancies
Joseph Gerard Jurcic · 2019 · Seminars in Nuclear Medicine
Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation
Jing Chen, Esther A. Zaal, Celia R. Berkers, Rob Ruijtenbeek, Johan Garssen, Frank A. Redegeld · 2021 · Cells
CD38 as an immunotherapeutic target in multiple myeloma
Francesca Bonello, Mattia D’Agostino, Maria Moscvin, Chiara Cerrato, Mario Boccadoro, Francesca Gay · 2018 · Expert Opinion on Biological Therapy
Treatment of relapsed and refractory multiple myeloma
Ji Hyun Lee, Sung‐Hyun Kim · 2020 · Blood Research
Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma
Na Yu, Yifan Zhang, Jiaying Li, Wenxing Gu, Shujing Yue, Bin Li, Fenghua Meng, Huanli Sun, Rainer Haag, Jiandong Yuan et al. · 2021 · Advanced Materials
Successful treatment with daratumumab for post‐HSCT refractory hemolytic anemia
Ehud Even‐Or, Adeeb NaserEddin, Bella Shadur, Yael Dinur Schejter, Mohammad Najajreh, Orly Zelig, Irina Zaidman, Polina Stepensky · 2019 · Pediatric Blood & Cancer
New Agents in Multiple Myeloma: An Examination of Safety Profiles
Sara Bringhen, Edwin de Wit, Meletios Athanasios Dimopoulos · 2017 · Clinical Lymphoma Myeloma & Leukemia
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Klara Kropivšek, Paul Kachel, Sandra Götze, Rebekka Wegmann, Yasmin Festl, Yannik Severin, Benjamin D. Hale, Julien Mena, Audrey van Drogen, Nadja Dietliker et al. · 2023 · Nature Cancer
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Philippe Moreau, Niels W.C.J. van de Donk, Jesús F. San Miguel, Henk M. Lokhorst, Hareth Nahi, Dina Ben‐Yehuda, Michèle Cavo, Gordon Cook, Michel Delforge, Hermann Einsele et al. · 2016 · Drugs
NF-κB dysregulation in multiple myeloma
Geoffrey M. Matthews, Ricardo De Matos Simoes, Eugen Dhimolea, Michal Sheffer, Sara Gandolfi, Olga Dashevsky, Jeffrey Sorrell, Constantine S. Mitsiades · 2016 · Seminars in Cancer Biology
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
Anja Seckinger, Jens Hillengaß, Martina Emde, Susanne Beck, Christoph Richard Kimmich, Tobias Dittrich, Michael Hundemer, Anna Sophia Jauch, Ute Hegenbart, Marc‐Steffen Raab et al. · 2018 · Frontiers in Immunology
Emerging drugs and combinations to treat multiple myeloma
Alessandra Larocca, Roberto Mina, Francesca Gay, Sara Bringhen, Mario Boccadoro · 2017 · Oncotarget
Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice
Jonathan R. Genzen, David L. Murray, György Ábel, Qing H. Meng, Richard J. Baltaro, Daniel D. Rhoads, Julio C. Delgado, Rhona J. Souers, Christine P. Bashleben, David F. Keren et al. · 2017 · Archives of Pathology & Laboratory Medicine
Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti–Interferon-γ Autoantibodies
Sebastian Ochoa, Li Ding, Samantha Kreuzburg, Jennifer D. Treat, Steven M. Holland, Christa S. Zerbe · 2020 · Clinical Infectious Diseases
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
Tomáš Jelı́nek, Roman Hájek · 2016 · OncoImmunology
Daratumumab for the treatment of multiple myeloma
Cyrille Touzeau, Philippe Moreau · 2017 · Expert Opinion on Biological Therapy
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J. Costa, Yi Lin, Robert Frank Cornell, Thomas G. Martin, Saurabh Chhabra, Saad Z. Usmani, Sundar Jagannath, Natalie S. Callander, Jesús G. Berdeja, Yubin Kang et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
Stephanos Vassilopoulos, Athanasios Vassilopoulos, Markos Kalligeros, Fadi Shehadeh, Eleftherios E Mylonakis · 2022 · Open Forum Infectious Diseases
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
Sanne J. de Haart, Lisa C. Holthof, Willy A. Noort, Monique C. Minnema, Maarten E. Emmelot, Tineke Aarts‐Riemens, Parul D Doshi, Kathy Sasser, Huipin Yuan, Joost Dick de Bruijn et al. · 2016 · Haematologica
Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma
Anna Mansour, Abdelilah Wakkach, Claudine Blin‐Wakkach · 2017 · Frontiers in Immunology
How I treat the young patient with multiple myeloma
Sara Gandolfi, Claudia Paba Prada, Paul Gerard Guy Richardson · 2018 · Blood
Infectious and immunological sequelae of daratumumab in multiple myeloma
Andrew J. Johnsrud, Joyce J. Johnsrud, Sandra P. Susanibar-Adaniya, Jorge Jo Kamimoto, Atul Kothari, Mary Burgess, Frits van Rhee, Juan Carlos Rico · 2018 · British Journal of Haematology
Daratumumab in untreated newly diagnosed multiple myeloma
Nadine H. Abdallah, Shaji Kunnathu Kumar · 2019 · Therapeutic Advances in Hematology
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
Noémie Leblay, Ranjan Maity, Fajer Hasan, Paola E. Neri · 2020 · Frontiers in Oncology
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Jakub Radocha, Niels W.C.J. van de Donk, Katja Christina Weisel · 2021 · Cancers
Immunotherapy in Multiple Myeloma
Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Sanjay De Mel, Wee Joo Chng · 2020 · Cells
Is immunotherapy here to stay in multiple myeloma?
Paula Rodríguez‐Otero, Bruno Paiva, Monika Martha Engelhardt, Felipe Prósper, Jesús F. San Miguel · 2017 · Haematologica
Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma
Kristine A. Frerichs, Monique C. Minnema, Mark‐David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Tuna Mutis, Christie P.M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman et al. · 2021 · Blood Advances
Progress in Myeloma — A Monoclonal Breakthrough
Rajkumar, S. Vincent, Kyle, Robert A. · 2016 · New England Journal of Medicine
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia
Ernest Moles, Christopher B. Howard, Pie Huda, Mawar Karsa, Hannah McCalmont, Kathleen Kimpton, Alastair M. P. Duly, Yongjuan Chen, Yizhou Huang, Melinda L. Tursky et al. · 2023 · Science Translational Medicine
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma
Tiantian Zhang, Sen Wang, Teng-Fei Lin, Jingmei Xie, Lina Zhao, Zhuoru Liang, Yangqiu Li, Jie Jiang · 2017 · Oncotarget
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era
Li Zhang, Yu‐Tzu Tai, Matthew Ho, Lugui Qiu, Kenneth Carl Anderson · 2017 · Experimental Hematology and Oncology
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Kristine A. Frerichs, Noemi Anna Nagy, Pieter L. Lindenbergh, Patty Bosman, Jhon A. Marin Soto, Marloes E.C. Broekmans, Richard W.J. Groen, Maria Themeli, Louise Nieuwenhuis, Claudia A.M. Stege et al. · 2018 · Expert Review of Clinical Immunology
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab
Ajay K. Nooka, Charise L. Gleason, Marva Ollivierre Sargeant, Michelle Walker, Melanie Watson, Elyse Hall Panjic, Sagar Lonial · 2018 · Journal of Oncology Practice
New Drugs in Multiple Myeloma
Chutima Kunacheewa, Robert Zygmunt Orlowski · 2019 · Annual Review of Medicine
The tumour immune microenvironment in oesophageal cancer
Maria Davern, Noel Edward Donlon, Robert F. Power, Conall Hayes, Ross King, Margaret R. Dunne, John Vincent Reynolds · 2021 · British Journal of Cancer
HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
Nizar Joher, Marie Matignon, Philippe Grimbert · 2021 · Frontiers in Immunology
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
Massimo Offidani, Laura Corvatta, Sonia Morè, Attilio Olivieri · 2021 · Drug Design Development and Therapy
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
Hiroko Nishida, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada · 2018 · Blood Cancer Journal
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
Kamlesh Kumar Bisht, Brian A. Walker, Shaji Kunnathu Kumar, Ivan Špıčka, Philippe Moreau, Tom G. Martin, Luciano J. Costa, Joshua Ryan Richter, Taro Fukao, Sandrine Macé et al. · 2021 · Expert Review of Hematology
New Biological Therapies for Multiple Myeloma
Alfred L. Garfall · 2023 · Annual Review of Medicine
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma
Ajai Chari, Suzanne A. Arinsburg, Sundar Jagannath, Toshihisa Satta, Ivey Treadwell, Donna Catamero, Gillian Morgan, Huaibao Feng, Clarissa Uhlar, Imran Khan et al. · 2017 · Clinical Lymphoma Myeloma & Leukemia
Novel biomarkers in multiple myeloma
Adam Levin, Parameswaran Hari, Binod Dhakal · 2018 · Translational research
Daratumumab in Primary Effusion Lymphoma
Nirav Niranjan Shah, Arun K. Singavi, Alexandra M. Harrington · 2018 · New England Journal of Medicine
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Gilles A. Salles, Ajay K. Gopal, Monique C. Minnema, Karen Wakamiya, Huaibao Feng, Jordan Mark Schecter, Michael L. Wang · 2019 · Clinical Lymphoma Myeloma & Leukemia
BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma
Yang Wang, Hui Joyce Li, Wei Feng Xu, Mingzhu Pan, Chun Qiao, Jialing Cai, Jingjing Xu, Min Wang, Juan Zhang · 2020 · Journal of Immunotherapy
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Zhaoyun, Xu, Xintong, Liu, Hui, Zhao, Xianghong, Yang, Chun, Fu, Rong · 2023 · Experimental Hematology & Oncology
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tianyu Song et al. · 2024 · Nature Communications
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
Marit Jalink, Chaja Feige Jacobs, Jahanzaib Khwaja, Dorothea Evers, Coty Bruggeman, Bruno Fattizzo, Marc Michel, Étienne Crickx, Quentin A. Hill, Ulrich Jaeger et al. · 2024 · Blood Advances
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors
Francesca Gay, Mattia D’Agostino, Luisa Giaccone, Mariella Genuardi, Moreno Benedetto Festuccia, Mario Boccadoro, Benedetto Bruno · 2017 · Clinical Lymphoma Myeloma & Leukemia
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Myo Htut, Anita D’Souza, Amrita Y. Krishnan, Benedetto Bruno, Mei‐Jie Zhang, Mingwei Fei, Miguel Ángel Díaz, Edward Alan Copelan, Siddhartha Ganguly, Mehdi Hamadani et al. · 2017 · Transplantation and Cellular Therapy
The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation
Sanjay De Mel, Gwyneth Shook-Ting Soon, Yingting Mok, Tae‐Hoon Chung, Anand Devaprasath D. Jeyasekharan, Wee-Joo Chng, Siok‐Bian Ng · 2018 · International Journal of Molecular Sciences
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer Martin Mark, Amrita Y. Krishnan, Keith E Stockerl-Goldstein, Saad Z. Usmani, Anil Londhe, Delores Etheredge, Sarah Fleming, Baolian Liu et al. · 2018 · Cancer
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Omar S. Al‐Odat, Max Von Suskil, Robert J. Chitren, Weam Othman Elbezanti, Sandeep Kumar Srivastava, Tülin Budak-Alpdoǧan, Subash C. Jonnalagadda, Bharat Bhushan Aggarwal, Manoj Kumar Pandey · 2021 · Frontiers in Pharmacology
Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab
David B. Sykes, Wilfried Schroyens · 2018 · New England Journal of Medicine
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus
Julius Lindblom, Daniel Toro Dominguez, Elena Carnero‐Montoro, Lorenzo Beretta, María Orietta Borghi, Jessica Castillo, Yvonne Enman, Chandra Mohan, Marta Eugenia Alarcón-Riquelme, Guillermo Barturen et al. · 2023 · Journal of Autoimmunity
CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies
Wenpeng Huang, Tianyao Wang, Yongkang Qiu, Chenzhen Li, Bo Chen, Lele Song, Qi Yang, Xinyao Sun, Bing Jia, Lei Kang · 2024 · European Journal of Nuclear Medicine and Molecular Imaging
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Robert Zygmunt Orlowski, Sagar Lonial · 2016 · Clinical Cancer Research
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma
Serena Rocchi, Paola Tacchetti, Lucia Pantani, Katia Mancuso, Beatrice Anna Zannetti, Michèle Cavo, Elena Zamagni · 2018 · Haematologica
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel C. Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi et al. · 2018 · Blood
The Anti-CD38 Antibody Therapy in Multiple Myeloma
Maria Teresa Petrucci, Federico Vozella · 2019 · Cells
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model
Megan Minnix, Vikram Adhikarla, Enrico Caserta, Erasmus Kofi Poku, Russell C. Rockne, John E. Shively, Flavia Pichiorri · 2020 · Journal of Nuclear Medicine
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
Chantal Reina-Ortiz, Michael Constantinides, Alexis Fayd’herbe de Maudave, Jessy Présumey, Javier Hernández, Guillaume Cartron, David Giraldos, Rosana Díez, Isabel Izquierdo, Gemma Azaceta et al. · 2020 · OncoImmunology
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Hannah A. Blair · 2017 · Drugs
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Jesús F. San Miguel, Saad Z. Usmani, María‐Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu et al. · 2020 · Haematologica